ADx NeuroSciences and Alamar Biosciences Announce Partnership to Provide Customized Blood-Based Biomarker Assay Solutions to Accelerate Biopharma Clinical Development
Collaboration will expand access to high sensitivity NULISA immunoassays for clinical biomarker analysis.
ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a leader in ultra-sensitive immunoassay technologies, today announced a partnership in the development of customized biomarker assay solutions using Alamar’s NULISA™ (Nucleic Acid Linked Immuno-Sandwich Assay) immunoassay platform and ARGO™ HT System. This collaboration aims to provide advanced tools for the detection and quantification of critical biomarkers to support neurological disease therapeutic development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241027884281/en/
ADx NeuroSciences logo (Graphic: Business Wire)
Under the terms of the partnership, Alamar Biosciences and ADx NeuroSciences will combine their respective expertise to provide tailored assay solutions to meet the specific needs of pharmaceutical companies advancing novel therapeutics for neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS.
"We are excited to partner with ADx NeuroSciences, a recognized leader in the field of neurodegenerative biomarker research," said Dr. Yuling Luo, Chairman and CEO of Alamar Biosciences. "By combining our NULISA platform's ultra-sensitive detection capabilities with ADx’s extensive expertise in neuroscience antibody and assay development, we aim to accelerate the development of biomarker assays that can facilitate the development and approval of disease modifying therapies for neurodegenerative diseases.”
Koen Dewaele, CEO of ADx NeuroSciences, commented, "Our collaboration with Alamar Biosciences marks a significant step forward in our mission to support pharmaceutical companies advancing their therapeutic programs. Every phase in the search for a therapeutic, from preclinical work up to the launch of the ultimate drug, requires specific biomarker tools. By working with various technology platforms, we are able to make our biomarker assays available on the right technology at the right time. By adding the NULISA platform with its remarkable sensitivity to our range of possible platforms, it enforces our capabilities to support our pharma network in their search for tailor-made biomarkers."
This strategic collaboration highlights both companies' commitment to advancing biomarker detection and expanding the possibilities for early diagnosis and treatment of neurodegenerative diseases. By harnessing the power of the NULISA platform, Alamar Biosciences and ADx NeuroSciences aim to deliver cutting-edge solutions that will benefit clinical research and aid in the development of novel therapeutics.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA Platform along with the ARGO™ HT System works seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the high sensitivity protein detection technologies on the market today. For more information, please visit alamarbio.com.
About ADx NeuroSciences NV
ADx NeuroSciences is specialized in the research and development of neurodegenerative biomarker tools for diseases such as Alzheimer's and Parkinson's. Its expertise is used by pharmaceutical and diagnostic companies across the world for the conception, development, production, and worldwide commercialization of novel biomarkers, supporting the development of promising drugs, either by monitoring the drug effect or by selecting the right patients at a very early stage of the disease. These assays can be applied to a variety of platforms from research up to IVD use. The company was founded in 2011 and was acquired in 2022 by Fujirebio, a member of H.U. Group Holdings Inc., which is listed on the Tokyo Stock Exchange (TSE: 4544). For more information, please visit www.adxneurosciences.com.
About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality IVD testing with more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products. Fujirebio was the first company to develop and market CSF biomarkers for AD testing, under the Innogenetics brand, over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated neurodegenerative disease assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools. For more information, please visit www.fujirebio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241027884281/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of AOC to Nippon Paint Holdings28.10.2024 12:00:00 CET | Press release
Lone Star Funds (“Lone Star”) today announces the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell AOC, a leading global specialty chemicals company, to Nippon Paint Holdings Co., Ltd. (“NPHD”). AOC is a leading manufacturer of specialty chemical formulations in the unsaturated polyester and vinyl ester sectors. With operations in North America, Europe and Asia, AOC serves customers globally in the infrastructure, construction (residential and commercial), transportation, and recreation sectors. Under Lone Star’s stewardship, AOC invested in its core business systems, including commercial excellence, innovation, procurement and manufacturing efficiency, to drive earnings growth. AOC also invested in the expansion of its executive leadership team, broadening the capabilities of the team to efficiently manage the global enterprise. AOC is poised to capitalize on its next leg of growth, supported by a well-capitalized asset base and a world-class manageme
Delta-Fly Pharma Inc.: Phase I/II Study of DFP-10917 and Venetoclax in AML Patients Begins with Promising Initial Data28.10.2024 12:00:00 CET | Press release
Following to the previous information on September 10th. 2024, we are excited to share our latest development status. Enrollment of patients is progressing smoothly into the Phase I portion of the Phase I/II study of DFP-10917 combined with Venetoclax in AML patients previously treated with Venetoclax, one regimen. The first three patients are showing encouraging safety and efficacy results suggested further promising development. The existing standard combination chemotherapy for AML patients is Azacitidine and Venetoclax, but it is not comfortable for AML patients. We’re trying to do a combination of DFP-10917 with Venetoclax, as an alternative safer AML therapy, objective NDA approval from the FDA in the US under possible collaboration with a global mega-pharma. The Phase III study of DFP-10917 in relapsed/refractory AML patients is planned data cut-off as decreasing in the number of long-term survivors since then. Please take notice of our own innovative approach for miserable canc
PMI Worldwide Brands, LLC (dba, Stanley 1913) Partners with Kinaxis to Strengthen Supply Chain28.10.2024 12:00:00 CET | Press release
Stanley 1913, a subsidiary of HAVI, aligns with supply chain orchestrator to meet ever-growing consumer demand Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain orchestration, today announced that Stanley 1913 has selectedKinaxis to modernize its supply chain and ensure operational efficiencies to help ever-increasing consumer demand. Stanley 1913 innovates, designs and manufactures food and drinkware, including its iconic Quencher H2.0 FlowState™ Tumbler and innovative Stanley Cross Bottle. The global brand’s products are distributed in more than 60 countries worldwide. The Kinaxis Maestro™ platform will empower the Stanley 1913 team to sense potential supply chain hurdles quickly, analyze impacts and mitigation options, and implement rapid actions to address or prevent challenges that impact supply. “We have explored the use of advanced predictive analytics through machine learning and artificial intelligence, allowing us to gain end-to-end supply chain visibility
BeiGene Mourns Death of Beloved Board Member Donald Glazer28.10.2024 11:00:00 CET | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to share the news that Donald Glazer recently passed away. Don was a Board member and the chair of the nominating and corporate governance committee. Co-founder, Chairman and CEO John V. Oyler issued the following statement: “We are saddened by the passing of our dear friend, Don Glazer. He helped guide the founding of the company in 2010 and was an ardent supporter of our mission to deliver innovative medicines faster and more affordably to patients around the world. His impact from a professional and personal perspective is immeasurable, and he will be deeply missed by all of us who benefited from his extensive experience, sound judgment and wise counsel. We extend our heartfelt condolences to his family during this difficult time.” Mr. Glazer served as a passionate BeiGene Board member, building connections amongst broad networks of cancer doctors – including his own – around the world. He
Transition Industries LLC and Mitsubishi Gas Chemical announce Letter of Intent for a long-term Methanol Sales Agreement from the Pacifico Mexinol project in Sinaloa, Mexico28.10.2024 10:00:00 CET | Press release
Transition Industries LLC announced that it has signed a Letter of Intent (LOI) with Mitsubishi Gas Chemical Company, Inc. (MGC) to enter into a long-term Methanol Sales Agreement (MSA). Under the MSA, Transition Industries intends to supply MGC approximately 1 million MT per annum of ultra-low carbon methanol from its Pacifico Mexinol project, a 6,145 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico, expected to be in operation in 2028. Transition Industries is jointly developing Pacifico Mexinol with the International Finance Corporation (IFC), a member of the World Bank Group. The terms of the LOI and MSA were not disclosed. When it initiates operations, Pacifico Mexinol is expected to be the largest single ultra-low carbon chemicals facility in the world - producing approximately 350,000 MT of green methanol and 1.8 million MT of blue methanol annually from natural gas with carbon capture. Rommel Gallo, CEO of Transition Industries, commented: “We are pleas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom